These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 12564455

  • 1. Re: Gómez-Gerique, et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis 2002;162:245-51.
    Moriarty PM, Backes JM.
    Atherosclerosis; 2003 Jan; 166(1):201. PubMed ID: 12564455
    [No Abstract] [Full Text] [Related]

  • 2. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia.
    Gómez-Gerique JA, Ros E, Oliván J, Mostaza JM, Vilardell M, Pintó X, Civeira F, Hernández A, da Silva PM, Rodriguez-Botaro A, Zambón D, Lima J, Díaz C, Aristegui R, Sol JM, Chaves J, Hernández G, ATOMIX Investigators.
    Atherosclerosis; 2002 Jun; 162(2):245-51. PubMed ID: 11996943
    [Abstract] [Full Text] [Related]

  • 3. Comparison of endothelial function in patients with metabolic syndrome on bezafibrate or atorvastatin therapy.
    Hanefeld C, Bulut-Streich N, Bulut D, Graf C, Mügge A, Spiecker M.
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):153-5. PubMed ID: 16025235
    [No Abstract] [Full Text] [Related]

  • 4. Chitotriosidase genotype and serum activity in subjects with combined hyperlipidemia: effect of the lipid-lowering agents, atorvastatin and bezafibrate.
    Canudas J, Cenarro A, Civeira F, Garcí-Otín AL, Arístegui R, Díaz C, Masramon X, Sol JM, Hernández G, Pocoví M.
    Metabolism; 2001 Apr; 50(4):447-50. PubMed ID: 11288040
    [Abstract] [Full Text] [Related]

  • 5. Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia.
    Nakamura T, Kodama Y, Takano H, Umetani K, Fujioka D, Saito Y, Kawabata K, Obata JE, Kitta Y, Kobayashi T, Mende A, Kugiyama K.
    Atherosclerosis; 2007 Aug; 193(2):449-51. PubMed ID: 16997309
    [No Abstract] [Full Text] [Related]

  • 6. [Atorvastatin lowers C-reactive protein in dislipemic patients with type 2 diabetes mellitus].
    Illán Gómez F, Alcaraz Tafalla MS, Pascual Díaz M, Carrillo Alcaraz A.
    Med Clin (Barc); 2004 Oct 23; 123(14):535-7. PubMed ID: 15535926
    [Abstract] [Full Text] [Related]

  • 7. Atorvastatin: a new agent for hyperlipidemia.
    Kupecz D.
    Nurse Pract; 1997 Nov 23; 22(11):87-8, 90, 93. PubMed ID: 9403876
    [No Abstract] [Full Text] [Related]

  • 8. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).
    Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceska R, Hradec J.
    Cardiovasc Res; 2001 Nov 23; 52(2):290-8. PubMed ID: 11684077
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients.
    Renders L, Mayer-Kadner I, Koch C, Schärffe S, Burkhardt K, Veelken R, Schmieder RE, Hauser IA.
    Nephrol Dial Transplant; 2001 Jan 23; 16(1):141-6. PubMed ID: 11209008
    [Abstract] [Full Text] [Related]

  • 11. A meta-analysis of randomized head-to-head trials of atorvastatin versus rosuvastatin for reductions in C-reactive protein.
    Takagi H, Umemoto T.
    Int J Cardiol; 2012 Jan 12; 154(1):78-81. PubMed ID: 22019059
    [No Abstract] [Full Text] [Related]

  • 12. Statin therapy works for patients who have type 2 diabetes.
    Korber KE.
    JAAPA; 2008 Oct 12; 21(10):58, 60. PubMed ID: 19024640
    [No Abstract] [Full Text] [Related]

  • 13. [Comment from the cardiologic viewpoint].
    Lüscher TF.
    Praxis (Bern 1994); 2009 Feb 04; 98(3):129-30. PubMed ID: 19180438
    [No Abstract] [Full Text] [Related]

  • 14. [Drug clinics. Drug of the month. Atorvastatin (Lipitor)].
    Scheen AJ.
    Rev Med Liege; 1998 Jun 04; 53(6):374-7. PubMed ID: 9713220
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Atorvastatin and fibrinogen--a small subgroup shows extreme response.
    Sinzinger H, Rodrigues M.
    Atherosclerosis; 1999 Aug 04; 145(2):415-7. PubMed ID: 10488971
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.